IMVT - NASDAQ

Immunovant, Inc.

IMVT·NASDAQ

$31.15

+1.2%

HealthcareBiotechnology

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$6.40B

EPS-2.7700

P/E Ratio-11.25

Earnings Date06/04/2026

imvt

Total Stockholders' Equity

Last Annual Value

852.59M

3-Year CAGR

33%

5-Year CAGR

17%

10-Year CAGR

89%

Adjust for Inflation

Immunovant, Inc. Competitors Analysis of Total Stockholders' Equity

IMVT · NASDAQ

Company	Total Stockholders' Equity	CAGR 3Y	CAGR 5Y	CAGR 10Y
Immunovant, Inc. NASDAQ:IMVT	852.59M	33.0%	16.8%	N/A
Soleno Therapeutics, Inc. NASDAQ:SLNO	450.12M	41.9%	90.8%	62.8%
Kymera Therapeutics, Inc. NASDAQ:KYMR	1.58B	58.7%	28.0%	N/A
Viking Therapeutics, Inc. NASDAQ:VKTX	639.06M	22.4%	25.9%	54.9%
Ultragenyx Pharmaceutical Inc. NASDAQ:RARE	-80.00M	N/A	N/A	N/A
Dyne Therapeutics, Inc. NASDAQ:DYN	972.13M	120.0%	21.4%	-7.2%
ACADIA Pharmaceuticals Inc. NASDAQ:ACAD	1.23B	41.7%	17.8%	9.0%
Crinetics Pharmaceuticals, Inc. NASDAQ:CRNX	992.08M	22.5%	24.5%	N/A
NewAmsterdam Pharma Company N.V. NASDAQ:NAMS	683.43M	33.3%	64.6%	N/A
Akero Therapeutics, Inc. NASDAQ:AKRO	750.11M	11.9%	34.7%	N/A
Praxis Precision Medicines, Inc. NASDAQ:PRAX	878.14M	132.7%	28.5%	N/A

Immunovant, Inc. Fair Value Envelope

IMVT · NASDAQ

Our analysis suggests that IMVT has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $31.15, this represents a potential HIDDEN relative to our calculated worth for Immunovant, Inc..

HIDDEN

Intrinsic Value

Current Price: $31.15

Related Guides

Blog Categories

Continue your IMVT research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.